Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Synthetic Fungal Compounds Show Potent Anticancer Potential

By BiotechDaily International staff writers
Posted on 12 Mar 2013
Recent advances in the chemical synthesis of rare fungal compounds have yielded an exciting new class of reagents with potent anticancer properties.

Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) have been working with a class of fungal compounds called epipolythiodiketopiperazine (ETP) alkaloids. However, until recently the small amounts of these compounds that are produced naturally have made it difficult to do a comprehensive study of the relationship between the compounds' structure and their activity.

In a paper published in the January 24, 2013, online edition of the journal Chemical Science the investigators reported the development and application of a flexible and scalable synthetic technique, which allowed the construction of dozens of ETP derivatives.

Sixty of these compounds were tested against two different human cancer cell lines—cervical cancer and lymphoma. Many ETP derivatives demonstrated potent anticancer activity and killed cancer cells via induction of apoptosis. The most effective 25 compounds were tested against three additional lines, from lung, kidney, and breast tumors.

Overall, dimeric compounds appeared to be more effective at killing cancer cells than monomers, and compounds with at least two sulfur atoms were more effective than those with only one sulfur atom. Compounds lacking sulfur did not kill tumor cells efficiently. The active compounds were found to be approximately 1,000 times more toxic to cancer cells than they were to normal cells.

Several traits that bode well for the translational potential of the ETP class of natural products include concise and efficient synthetic access, potent induction of apoptotic cell death, activity against a wide range of cancer types, and a broad tolerance for modifications at multiple sites that should facilitate small-molecule drug development, mechanistic studies, and evaluation in vivo.

"What was particularly exciting to us was to see, across various cancer cell lines, that some of them are quite potent," said first author Dr. Mohammed Movassaghi, professor of chemistry at the Massachusetts Institute of Technology. "There is a lot of data out there, very exciting data, but one thing we were interested in doing is taking a large panel of these compounds, and for the first time, evaluating them in a uniform manner. We can go in with far greater precision and test the hypotheses we are developing in terms of what portions of the molecules are most significant at retaining or enhancing biological activity."

Related Links:

Massachusetts Institute of Technology



Channels

Genomics/Proteomics

view channel
Image: Cholesterol–shown here in hamster ovary cells—is a building block of steroid hormones that trigger puberty and support pregnancy (Photo courtesy of Dr. D. Ory, Washington University School of Medicine).

Cholesterol Trafficking in the Mouse Embryo Is Regulated by a snoRNA

Cellular cholesterol trafficking in mouse embryos was found to be regulated by U17 snoRNA. Small nucleolar RNAs (snoRNAs) are a class of small RNA molecules that primarily guide chemical modifications... Read more

Business

view channel

License Agreement to Promote Development of Therapeutic CDK Inhibitors

A license agreement has been signed that was designed to promote the development and commercialization of a series of highly-selective cyclin-dependent kinase 7 (CDK7) inhibitors for the treatment of cancer, inflammation, and viral infections. Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle control... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.